Harbour BioMed and Otsuka to Advance Bispecific T-Cell Engager for Autoimmune Diseases
Harbour BioMed has entered into a global strategic collaboration with Otsuka Pharmaceutical Co., Ltd., granting Otsuka exclusive rights to develop,
Read moreHarbour BioMed has entered into a global strategic collaboration with Otsuka Pharmaceutical Co., Ltd., granting Otsuka exclusive rights to develop,
Read moreSanofi has announced a definitive agreement to acquire Blueprint Medicines, a U.S.-based biopharmaceutical company focused on systemic mastocytosis (SM) and
Read moreSwiss pharmaceutical company Roche has announced plans to advance its experimental antibiotic, zosurabalpin, into Phase 3 clinical trials. Developed in
Read moreSanofi has announced a definitive agreement to acquire clinical-stage biotech firm Vigil Neuroscience, Inc., in a move to expand its
Read moreBioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire clinical-stage biotech Inozyme Pharma, Inc. for approximately $270 million
Read moreIn a strategic move to expand its oncology pipeline, GSK plc (LSE/NYSE: GSK) announced on Tuesday, it has entered into
Read moreGlobal biopharmaceutical leader AstraZeneca has officially opened a new $300 million state-of-the-art cell therapy manufacturing facility in Rockville, Maryland, marking
Read moreMerck KGaA is moving forward with the acquisition of SpringWorks Therapeutics, confirming a definitive agreement at $47 per share in
Read moreIn a transformative move for the U.S. healthcare manufacturing sector, Roche unveiled plans to invest $50 billion in American pharmaceutical
Read moreEli Lilly and Company announced groundbreaking Phase 2 results for its investigational siRNA therapy lepodisiran, which reduced lipoprotein(a) [Lp(a)] levels
Read more